CIRM Funded Clinical Trials

Phase 1 Safety Assessment of CPCB-RPE1, hESC-derived RPE Cell Coated Parylene Membrane Implants, in Patients with Advanced Dry Age Related Macular Degeneration


Mark Humayun
Investigator:
CIRM Grant:
Award Value:
$18,922,665
Trial Stage: 
Phase 1
Trial Status: 
Recruiting
Targeted Enrollment:
20
ClinicalTrials.gov ID:
Details: 

Age-related macular degeneration is a progressive disease resulting in death of the retinal pigment epithelium (RPE) causing distortion to central vision and eventually to legal blindness. Incidence - 1:1359 in the US. Approach is replacement therapy with viable RPE cells delivered on a synthetic membrane mimicking native state with RPE cells on Bruch's membrane.

Design: 

Open label, single arm study.

Goal: 

Safety. Efficacy - slow disease progression, maintain and restore visual acuity

Status: 

Currently Enrolling